Hertab 250 mg contains Lapatinib, a dual tyrosine kinase inhibitor that targets both HER2 (ErbB2) and EGFR (ErbB1) receptors. It is commonly used in patients with advanced or metastatic HER2-positive breast cancer, especially after progression on prior therapies.

🔬 Mechanism of Action

Lapatinib inhibits intracellular tyrosine kinase domains of HER2 and EGFR receptors. As a result, it:

• Blocks tumor cell signaling pathways
• Inhibits cancer cell proliferation
• Promotes apoptosis (cell death)

This dual inhibition helps control tumor growth in HER2-driven cancers.

💊 Indications

Hertab 250 mg is indicated for:

• HER2-positive advanced or metastatic breast cancer
• Often used in combination with capecitabine or letrozole depending on patient profile
• Patients who have received prior treatments including trastuzumab

📌 Key Features of Hertab 250 mg

• Strength: 250 mg
• Dosage Form: Oral tablet
• Therapeutic Class: Dual Tyrosine Kinase Inhibitor (HER2/EGFR)
• Administration: Taken orally once daily as prescribed
• Monitoring: Liver function tests and cardiac monitoring recommended

⚕️ Benefits of Lapatinib

• Targeted therapy for HER2-positive breast cancer
• Oral administration for convenience
• Effective in patients resistant to prior HER2 therapies
• Helps delay disease progression

⚠️ Precautions for Hertab 250 mg

• Risk of diarrhea, rash, and fatigue
• Potential hepatotoxicity
• Cardiac function monitoring required
• Drug interactions possible
• Use strictly under oncologist supervision

Hertab 250 mg (Lapatinib Tablets) provides an effective targeted treatment option for HER2-positive breast cancer, helping improve disease control and patient outcomes when used under specialized oncology care.